Compare ACADIA Pharmaceuticals Inc. (ACAD) vs KLA Corp. (KLAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs KLA Corp. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while KLA Corp. trades at $220.98 (market cap $282.77B). The key difference: KLA Corp. is far larger — about 63× ACADIA Pharmaceuticals Inc.'s market cap, and KLA Corp. pays a 0.43% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | KLAC | |
|---|---|---|
Market Cap | $4.49B | $282.77B |
Sector | Health | Technology |
52-Week High | $28.06 | $301.71 |
52-Week Low | $20.06 | $84.39 |
Enterprise Value | $3.69B | $283.96B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
KLA Corporation (KLAC) trades at $216.47, down 8.1% over 24 hours, amid a broader semiconductor selloff. The stock maintains strong fundamentals with a 35.66% net income margin and consistent earnings beats, including Q1 2026 EPS of $0.94 versus $0.917 expected. A 1:10 stock split is scheduled for June 12, 2026, and the company pays a $2.30 dividend. Technical indicators show a bearish short-term trend with support near $209.
KLAC's outlook is supported by robust profitability and AI-driven demand, but high valuation ratios (P/E 66.07) pose risks. Analyst consensus is bullish with a $228.42 price target, though sector volatility and competitive pressures require monitoring. The stock offers growth potential tempered by market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
